Navigation Links
Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase

PALO ALTO, Calif., Feb. 28, 2011 /PRNewswire/ -- Varian Medical Systems, Inc. (NYSE: VAR) today announced that it has entered into a new agreement with Bank of America N.A. to repurchase $280 million of its common stock under an accelerated share repurchase program.  

Under the accelerated repurchase agreement, Varian will pay $280 million to Bank of America N.A. and receive approximately 3.5 million shares, or 85% of the shares to be repurchased based on the closing share price of the company's common stock on February 23, 2011.  The total number of shares ultimately repurchased under the agreement will be determined upon final settlement.  Varian will either receive additional shares of common stock or under certain circumstances be required to remit a settlement amount payable at Varian's option in cash or common stock, based generally on the volume weighted average share price of Varian's common stock during the next two to six months.  

"Given the success of Varian's first accelerated repurchase program and the ongoing strength of Varian's balance sheet in a low interest rate environment, we have another opportunity to return stockholder value through a second accelerated repurchase program," said Tim Guertin, president and CEO of Varian Medical Systems.

The shares of common stock will be acquired under the remainder of the 8 million share repurchase authorization approved by the company's Board of Directors on August 6, 2010 (which expires at the end of the Company's fiscal year 2011), and, if necessary, the 12 million share repurchase authorization approved by the Company's Board of Directors on February 11, 2011 (which expires at the end of the Company's fiscal year 2012).  Shares purchased under the accelerated share repurchase program will be retired.

The repurchase will be financed partially from cash on hand and partially with borrowings from the company's revolving credit facility.

As of the end of the first quarter of its fiscal year 2011, the company had 121.2 million fully diluted shares outstanding.  Since initiating share repurchases at the end of fiscal year 2001, the company has spent approximately $2.0 billion to repurchase 48 million shares of common stock at an average price of $42.54 per share.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,400 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit

Forward-Looking Statements Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning future financial results and any statements using the terms "expect," "will," "believe," "estimate," or similar statements, are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the volume-weighted average share price through expected completion of the repurchase agreement, the actual completion date of the repurchase agreement, the final number of shares repurchased, the aggregate cost to the company, whether the company elects to satisfy any settlement payment in cash or in stock, and the company's ability to generate cash flow, and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise. FOR INFORMATION CONTACT:Spencer Sias   (650)

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University
2. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 12 Million Shares of Stock Through Fiscal Year 2012; Additional Accelerated Share Repurchase Program
3. BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers
4. Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems
5. Varian Medical Systems Security and Inspection Products Group Receives Largest Single Order for IntellX Systems
6. Varian Medical Systems Announces X-Ray Products Contract With Toshiba Medical Systems
7. Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2011
8. Varian Medical Systems Schedules First Quarter FY2011 News Release and Conference Call
9. EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
10. For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
11. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/29/2015)... Jose, CA (PRWEB) , ... November 29, 2015 , ... ... Area, is proud to announce their December, 2015, featured apartment community: Epic. In showcasing ... for corporate housing in the tight Bay Area rental market to efficiently find housing ...
(Date:11/28/2015)... ... 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, ... savings of up to 20% off orders $80 or more to free gifts with purchases, ... hours. , As a competitive e-commerce website for skin care and cosmetic needs, customers will ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... and the University of British Columbia suggested that laws requiring bicyclists to wear helmets ... that part of the reason for the controversial conclusion is that, while helmets have ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... and convenient way to dispense prescription medications at home, so he invented the ... to monitor and dispense prescription medications. In doing so, it could help to ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
Breaking Medicine News(10 mins):